Rare blood clot risk: UK agency says under-30s to be offered non-AstraZeneca vaccine

By: |
April 07, 2021 8:25 PM

The United Kingdom's drug regulator says the AstraZeneca vaccine has huge benefits but people under 30 will be offered another product due to a rare blood clot risk.

AstraZeneca vaccine is currently in use in India and is being manufactured by the Serum Institute of India (SII) as part of its deal with AstraZeneca.AstraZeneca vaccine is currently in use in India and is being manufactured by the Serum Institute of India (SII) as part of its deal with AstraZeneca.

The United Kingdom’s drug regulator says the AstraZeneca vaccine has huge benefits but people under 30 will be offered another product due to a rare blood clot risk.

The Medicines and Healthcare Products Regulatory Agency said Wednesday that while it is studying the possible connection between AstraZeneca’s coronavirus vaccine and rare blood clots, the Pfizer and Moderna vaccines should be offered to people in that age group.

Dr June Raine, the head of he MHRA, says that the benefits “continue to outweigh the risks for the vast majority of people.”

The decision was announced soon after the European Union’s drug regulator said it had found a “possible link” between the AstraZeneca coronavirus vaccine and a rare clotting disorder. But that agency did not recommend any new restrictions on the vaccine for people 18 and over, saying the benefits of the shot still outweigh risks.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Modi, Biden express ‘deep pride’ on close cooperation between India, US to fight COVID pandemic
2Coronavirus (Covid-19) India Live News: Quad leaders welcome India’s decision to resume Covid-19 vaccine exports from October
3Novavax, Serum seek emergency use approval from WHO for Covid vaccine